Louise Nordfors describes several epigenetic mechanisms that have been described to be dysregulated in human disease and the rationale for BET protein inhibition to treat CV and renal disease.
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Louise Nordfors, PhD - Senior researcher at Renal Medicine, Karolinska University Hospital and the Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Epigenetics in CKD & CVD: A potential breakthrough therapy?Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Prof. Erik Stroes, MD
- Epigenetics in CKD & CVD: A potential breakthrough therapy?A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
Kamyar Kalantar-Zadeh, MD